Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
If you are interested in meeting with the Protagonist team during the conference, please reach out to your BTIG representative.NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the BTIG Virtual Biotechnology Conference.
加利福尼亚州纽瓦克/ACCESSWIRE/2024年7月22日/Protagonist Therapeutics, Inc.（纳斯达克股票代码：PTGX）（“主角” 或 “公司”）今天宣布，总裁兼首席执行官迪内什·帕特尔博士将参加BTIG虚拟生物技术会议的炉边谈话和一对一会议。
BTIG Virtual Biotechnology Conference - August 5-6, 2024
BTIG 虚拟生物技术会议-2024 年 8 月 5 日至 6 日
Format: Fireside Chat
Day/Time: Tuesday, August 6 at 2:00-2:35 P.M. EDT
格式：炉边聊天
日期/时间：美国东部时间 8 月 6 日星期二下午 2:00-2:35
If you are interested in meeting with the Protagonist team during the conference, please reach out to your BTIG representative.
如果您有兴趣在会议期间与Protagonist团队会面，请联系您的BTIG代表。
About Protagonist
关于主角
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and JNJ scientists jointly discovered PN-235 as part of Protagonist's Interleukin-23 receptor (IL-23R) antagonist collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were published in The New England Journal of Medicine in February 2024. The open-label extension (OLE) component of Phase 2 REVIVE study is ongoing, followed by an additional 2-year long-term extension (LTE) THRIVE study. Enrollment has been completed in the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda announced in January 2024.
Protagonist Therapeutics是一家生物制药公司，其基于肽的新化学实体（NCE）rusfertide和 JNJ-2113（前身为 PN-235）处于临床开发的后期3期阶段，均源自该公司的专有技术平台。Protagonist 和 JNJ 的科学家共同发现了 PN-235，这是 Protagonist 与 JNJ 合作的白细胞介素 23 受体 (IL-23R) 拮抗剂的一部分，并随后进行了支持 IND 的临床前和 1 期研究，JNJ 负责进一步的临床开发。Rusfertide是天然激素hepcidin的仿制品，是该公司目前处于真性红细胞增多症（PV）全球三期开发计划中的主要候选药物。第二阶段REVIVE研究的随机部分已成功完成，结果于2024年2月发表在《新英格兰医学杂志》上。REVIVE第二期研究的开放标签延期（OLE）部分正在进行中，随后又进行了一项为期两年的长期延期（LTE）THRIVE研究。对真性红细胞增多症中rusfertide的全球3期VERIFY研究的注册已经完成。根据2024年1月宣布的与武田签订的全球合作和许可协议，正在与武田共同开发Rusfertide并共同商业化。
More information on Protagonist and its pipeline drug candidates and clinical studies can be found on the Company's website at .
有关Protagonist及其即将上市的候选药物和临床研究的更多信息，请访问该公司的网站，网址为。
Investor Relations Contact
投资者关系联系人
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
科里·戴维斯博士
生命科学顾问
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
媒体联系人
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
virginiaamann@ententeinc.com
弗吉尼亚·阿曼，创始人/首席执行官
ENTENTE 公司网络
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics, Inc.
来源：Proganist Therapeutics, Inc.